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Abstract
Protein C (PC) and protein S (PS) are vitamin K-dependent glycoproteins, that act as natural anticoagulants. The 
proteolytic activation of PC by thrombin occurs on the surface of endothelial cells and involves thrombomodulin 
and endothelial PC receptor. In the presence of PS, phospholipids and calcium, activated PC (APC) inactivates 
membrane bound factor V (FVa) and FVIIIa by their cleavage at the specific arginine residues. PC and PS defi-
ciencies are inherited as autosomal dominant disorders associated with recurrent venous thromboembolism (VTE) 
and, in most cases, derived from heterozygous missense mutations (78% and 63%, respectively). Heterozygous PC 
deficiency is found in 6% of families with inherited thrombophilia, in 3% of patients with a first-time deep vein 
thrombosis (DVT) and in 0.2–0.3% of healthy individuals. The PS deficiency is detected more commonly than PC 
deficiency and its prevalence has been estimated with a less than 0.5% in the general European population and 
2% to 12% of selected groups of thrombophilic patients. Approximately 75% of PC-deficient patients have type 
I deficiency and 95% of PS-deficient patients develop type I and type III of PS deficiency. The diagnosis of PC and 
PS deficiencies is challenging due to many preanalytical and analytical factors affecting the PC/PS levels. Molecular 
analysis of the PC and PS genes (PROC and PROS1, respectively) involves direct gene sequencing and if nega-
tive, multiplex ligation-dependent probe amplification (MLPA) method is performed. Patients with low PC and 
PS levels and the known mutation within PROC or PROS1 genes combined with other genetic or environmental 
thrombosis factors are at increased risk of recurrent thromboembolic events and require lifelong oral anticoagula-
tion (Adv Clin Exp Med 2013, 22, 4, 459–467).
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Streszczenie
Białko C (protein C, PC) i białko S (protein S, PS) to zależne od witaminy K glikoproteiny będące naturalnymi inhi-
bitorami krzepnięcia krwi. Proteolityczna aktywacja PC przez trombinę zachodzi na powierzchni komórek śród-
błonka w obecności trombomoduliny i śródbłonkowego receptora PC. Aktywne PC (APC) z udziałem kofaktora, 
którym jest PS, w obecności fosfolipidów i wapnia, degraduje czynnik Va i FVIIIa przez ich cięcie w specyficznych 
resztach argininowych. Niedobory PC i PS są podłożem występowania i nawrotów żylnej choroby zakrzepowo-
zatorowej (ż.ch.z.z.). Niedobory PC/PS są dziedziczone w sposób autosomalny dominujący i w większości przy-
padków pochodzą z heterozygotycznych mutacji typu zmiany sensu (odpowiednio: 78 i 63%). Heterozygotyczny 
niedobór PC występuje u 6% rodzin z trombofilią, u 3% pacjentów, z pierwszym epizodem zakrzepicy żył głębokich 
oraz u 0,2–0,3% osób zdrowych. Niedobór PS pojawia się częściej niż niedobór PC, a jego występowanie szacuje 
się na mniej niż 0,5% w zdrowej populacji europejskiej i 2–12% u pacjentów z zakrzepicą. U około 75% pacjentów 
z niedoborem PC występuje niedobór typu I, a u 95% pacjentów z niedoborem PS rozwija się typ I i typ III niedo-
boru. Diagnostyka niedoborów PC i PS jest trudna ze względu na występowanie wielu czynników fazy przed- i ana-
litycznej wpływających na stężenia PC i PS. Analiza molekularna genów PC i PS (odpowiednio: PROC i PROS1) 
obejmuje ich bezpośrednie sekwencjonowanie genów, a w przypadku wyniku negatywnego stosuje się metodę 
multipleksowej amplifikacji sondy zależnej od ligacji (multiplex ligation-dependent probe amplification, MLPA). 
Pacjenci z małymi stężeniami PC i PS oraz mutacją w genach PROC lub PROS1 w połączeniu z innymi genetycz-
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Protein C (PC) and protein S (PS) are vitamin 
K-dependent glycoproteins that act as natural an-
ticoagulants. Basic characteristics of PC ad PS are 
summarized in Table 1.
Role of Protein C and 
Protein S in Human 
Physiology
PC is a precursor of the serine protease, acti-
vated protein C (APC). Its proteolytic activation 
by thrombin occurs on the surface of endothelial 
cells and involves thrombomodulin and endothe-
lial PC receptor (EPCr). PC activation is enhanced 
approximately 20-fold in vivo when PC is bound to 
the EPCr [1]. In the presence of PS, phospholipids 
and calcium, APC inactivates membrane bound 
activated factor (F)V and FVIII by their cleavage 
at the specific arginine residues [2]. only free PS 
that constitutes 40% of the total protein amount 
possesses APC cofactor activity [3].
Protein S also exerts a direct APC-indepen-
dent inhibitory effect on the prothrombinase com-
plex by binding to FXa and to FVa, and thus results 
in impaired prothrombin activation [4]. In addi-
tion, PS stimulates tissue factor pathway inhibitor 
(TFPI) in the inactivation of FXa [5].
Growing evidence indicates that PC, APC and 
PS, besides their known anticoagulant properties, 
have multiple actions such as anti-apoptotic and 
anti-inflammatory activities, regulation of gene 
expression and stabilization of endothelial barrier 
protection [6, 7]. This activity appears to be medi-
ated by two key receptors, protease activated re-
ceptor 1 (PAr1) and EPCr [6, 8]. Cytoprotective 
signaling induced by APC can be observed not on-
ly in the endothelium but also in many other cell 
types therein neurons, which may be a very prom-
ising tool for providing neuroprotective acute and 
chronic therapies [9].
PC and PS Deficiencies
Low levels of PC were first described by Grif-
fin et al. in 1981 [10]. PS deficiency was first re-
ported in 1984 by Comp and Esmon [11]. Both 
deficiencies were associated with recurrent venous 
thromboembolism (VTE). PC and PS deficien-
cies are inherited as autosomal dominant disor-
ders and, in most cases, derived from heterozy-
gous mutations.
Heterozygous PC deficiency is found in 6% 
of families with inherited thrombophilia, in 3% 
of patients with a first-time deep vein thrombosis 
(DVT) and in 0.2–0.3% of healthy individuals [12–
14]. PC/PS homozygosity or compound heterozy-
gosity is extremely rare (1/4 million of living in-
fants) and results in neonatal purpura fulminans 
(PF) and disseminated intravascular coagulation 
(DIC) presented within hours of birth [15, 16].
PC deficiency is classified as type I (quantita-
tive defects of PC: low antigen levels, reduced ac-
tivity) and type II (qualitative defects: IIa, normal 
antigen concentrations, reduced activity in both 
amidolytic and clotting functional assays, and IIb, 
normal antigen concentrations, reduced clotting 
activity) [12, 17]. Approximately 75% of PC-defi-
cient patients have type I deficiency and 95% of the 
remainding have type IIa deficiency, but type IIb is 
very rare [18].
The PS deficiency prevalence has been esti-
mated with a less than 0.5% in the general Euro-
pean population and 2% to 12% of selected groups 
of thrombophilic patients [19]. Currently, PS de-
ficiency is detected more commonly than PC de-
ficiency in the general population and among pa-
tients with VTE.
PS deficiency is classified as type I (low total 
and free antigen, reduced activity), type II (normal 
total and free antigen, reduced activity) and type 
III (normal total antigen, reduced free antigen and 
activity) [12, 20]. Type I and type III deficiencies 
account for 95% of cases of PS deficiency.
Acquired PC and PS deficiency can develop 
with vitamin K deficiency, liver disease, treatment 
with vitamin K antagonists, severe and chronic in-
flammation, autoimmune syndromes, nephritic 
syndrome, or DIC [14, 21]. of note, PC and PS 
deficiency cannot be reliably measured in patients 
receiving warfarin or acenocoumarol. Important-
ly, PS deficiency, but not PC deficiency, is com-
monly observed during pregnancy starting from 
the first weeks. Moreover, low PS levels can be 
found in patients with AIDS [22] and acute vari-
cella infection [23].
nymi i środowiskowymi czynnikami sprzyjającymi zakrzepicy są narażeni na zwiększone ryzyko nawracających 
epizodów zakrzepowo-zatorowych, co jest wskazaniem do stosowania przewlekłej antykoagulacji (Adv Clin Exp 
Med 2013, 22, 4, 459–467).
Słowa kluczowe: białko C, białko S, niedobór, zakrzepica żylna, mutacja.
Protein C and Protein S Deficiency 461
Genetic Background of PC 
and PS Deficiencies
recently, Caspers et al. have shown that PC 
and PS deficiencies exhibit similar mutation pro-
files and are most frequently caused by missense 
mutations (78% and 63%, respectively) followed 
by nonsense mutations (11% and 9%), splice-site 
mutations (7% and 13%), small duplications/in-
sertions/deletions (2% and 9%) and large deletions 
(3% and 6%) [13]. These data are in concordance 
with data published in the HGMD mutation data-
base (http://www.hgmd.org). The detection rate of 
Table 1. Main characteristics of protein C (PC) and protein S (PS) [3, 14, 18, 26]




isolated from bovine plasma by Johan 
Stenflo in 1976 and named protein 
C because it was the third protein to elute 
from DEAE-Sepharose 
described by Di Scipio in 1977, named 
protein S in reference to its isolation and 
characterization in Seattle
Gene characterization  
(Charakterystyka genu)
gene PROC located on chromosome 2, posi-
tion 2q13-q14, spans 11kb long including 
9 exons and 8 introns and encodes a 461 
amino acids protein
active gene PROS1 (or PSa) and tran-
scriptionally inactive pseudogene PROS2 
(or PSa) both located on chromosome 3, 
position 3p11.1-3q11.2 and share approxi-
mately 97% similarity; PROS1 gene spans 
80 kb long including 15 exons and 14 




hepatocytes, endothelial cells, mouse renal 
tubular cells 
hepatocytes, endothelial cells, human tes-
tis Leydig cells, vascular smooth muscle 
cells and megakaryocytes 
Molecular weight  
(Masa cząsteczkowa)
62 kDa 71 kDa
Protein  
(Białko)
the zymogenic form of plasma PC is 
activated by thrombin in the presence of 
thrombomodulin and endothelial protein 
C receptor leding to activated PC (APC) 
generation
60% bound to C4bBP-β chain (inactive), 
40% free PS (physiologically active), 
together total PS
Concentration in plasma  
(Stężenie w osoczu)
3–5 µg/ml 20–25 µg/ml 
Half-life  
(okres półtrwania)
6–8 hours 42 hours
reference range  
(Zakres referencyjny)
PC 70–140% free PS: female 55–124%, male 74–146%; 
total PS: female 60–140%, male 75–140% 
Assays  
(Testy)
amidolytic PC assays for routine screen-
ing for PC deficiency, more specific than 
coagulation assays; immunoassays (turbidi-
metric, nefelometric, ELISA) 
immunoassays for free and total PS, and 
clotting assays for PS activity 
Physiological variability  
(Zmienność fizjologiczna)
early childchood PC = 40%; increase by 
more than 20% in pregnancy and in the 
old age; remain elevated in the postpartum 
period
early childhood PS=60%, total PS is 
increasing with age; free PS levels are 
independent of age; pregnancy free PS 





VKA-based anticoagulant therapy, vitamin 
K deficiency, DIC, severe infections, liver 
disease, fresh thrombosis, oral contracep-
tive use, autoantibody presence
VKA-based anticoagulant therapy, vita-
min K deficiency, DIC, liver disease, oral 
contraceptive use, autoantibody presence
APC – activated PC. APC – aktywowane PC. 
DIC – disseminated intravascular coagulation. DIC – zespół rozsianego wewnątrznaczyniowego krzepnięcia. 
VKA – vitamin K antagonist. VKA – antagonista witaminy K.
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mutations is 70–80% for PC deficiency and around 
50% in families with PS deficiency [13, 24, 25].
The lower mutation rate detection within the 
PROS1 gene may be explained by the fact that PS 
levels are also influenced by non-genetic factors 
like age, sex, pregnancy, oral contraceptive use, or 
vitamin K intake [13, 26]. Moreover, some poly-
morphisms within the PROC and PROS1 genes, 
or within vitamin K-dependent gamma-carboxy-
lation-related genes, may affect PC and PS activity 
or antigen concentrations [27, 28].
Clinical Manifestations  
and Treatment of PC  
and PS Deficiencies
The risk of developing thrombosis among in-
dividuals with genetic defect in PROC or PROS1 
genes varies significantly and depends on multiple 
gene-gene or gene-environment interactions. Peo-
ple with hereditary PC/PS deficiency have about 
a 2- to 11-fold increased risk for VTE developing, 
with its main clinical presentations of DVT and 
pulmonary embolism (PE) in comparison with 
those without a deficiency [29]. This means that 
DVT or PE will occur in approximately 1 of every 
100 to 500 people with one of these deficiencies an-
nually [29]. Less common manifestations of PC/PS 
deficiency are superficial, cerebral, visceral, or axil-
lary vein thrombosis [26].
Depending on the phenotype, approximately 
half of the PC/PS deficient subjects become symp-
tomatic at 55 years of age, whereas others will 
never experience any complications [26, 30]. The 
development of VTE in PC/PS deficient patients 
may be provoked by concomitant thrombophilic 
defects (FV Leiden, prothrombin G20210A, in-
creased levels of FVIII, IX, and XI, hyperhomo-
cysteinemia) and exposure to transient risk fac-
tors (obesity, surgery, trauma, immobilization, 
chronic illnesses, pregnancy, or female hormone 
intake) [29, 31].
The large European Prospective Cohort on 
Thrombophilia (EPCoT) study has shown that 
4.5% of asymptomatic relatives of patients with 
confirmed thrombophilia, developed first VTE 
during the 5.7 years of follow-up [32]. The annu-
al incidence of VTE in PC- (0.7%) and PS- (0.8%) 
deficient patients was higher than in cases of FV 
Leiden [32].
Patients with provoked episodes are labeled as 
a low risk category and receive time-limited anti-
coagulation, usually 3 to 6 months of warfarin [33]. 
Warfarin should be administered initially with an 
additional injectable anticoagulant (usually low-
molecular-weight heparin, LMWH) until an in-
ternational normalized ratio (INr) of 2.0–3.0 is 
reached on two consecutive days. Heparin should 
be given for at least 5 days to prevent skin necro-
sis, which is a rare adverse effect that occurs dur-
ing early warfarin treatment in patients with PS/ 
/PC deficiency [26]. Patients with idiopathic events 
are considered at high risk for VTE recurrence 
and benefit from indefinite duration anticoagula-
tion [33, 34].
Patients with hereditary PC/PS deficiency have 
a high risk of VTE recurrence. A retrospective study 
in a large cohort of families has shown that annu-
al incidences of first recurrence after a first episode 
of VTE were 6.0% (95% CI, 3.9–8.7) in PC-defi-
cient patients and 8.4% (95% CI, 5.8–11.7) in PS-
deficient patients [30]. This risk has been increased 
1.4-fold by concomitance of other thrombophil-
ic defects e.g. FV Leiden, prothrombin G20210A 
compared to patients without concomitant throm-
bophilic defects [30].
Severe PC/PS deficiency when plasma PC/ 
/PS concentrations are almost undetectable is as-
sociated with PC/PS homozygosity or compound 
heterozygosity. This extremely rare condition 
causes PF and DIC and is characterized by gen-
eral clotting in the microvasculature [15, 16]. PF 
originates with red or purpuric lesions which rap-
idly progress to form palpable black eschars on the 
back of the head and buttocks. Coagulation stud-
ies have shown markedly elevated D-dimer, an 
undetectable plasma PC activity, thrombocytope-
nia, hypofibrinogenaemia, and prolongation of the 
prothrombin time [15].
Neonatal PF can be monitored only with PC 
replacement in the form of fresh frozen plasma 
(FFP) or a human plasma-derived, viral inacti-
vated PC concentrate (Ceprotin) [15]. Ceprotin 
is manufactured by Baxter BioScience (Glendale, 
CA, USA) and has been licensed in the United 
States and Europe.
replacement therapy with PC concentrate can 
be used at a dose of 100 U/kg followed by 50 U/kg 
every 6 hours to maintain a PC level of about 50%. 
If PC concentrate is unavailable, FFP is recom-
mended at a dose 10–15 ml/kg every 8–12 h. The 
most affected infants have been managed for long-
term secondary prophylaxis with PC concentrate 
or therapeutic anticoagulation using either LMWH 
or high-intensity warfarin [15]. Monitoring with 
D-dimer levels for evidence of coagulation activa-
tion is useful to confirm adequate replacement or 
anticoagulation therapy [35].
recombinant APC (Xigris; Eli Lilly, India-
napolis, IN, USA) has also been used to treat PF 
in a child with severe PC deficiency and 24 µg/ 
/kg/h dose has been administrated [36]. However, 
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potential hemorrhagic risk may be involved during 
this treatment [37].
Although PC/PS deficiency is associated pri-
marily with an increased risk for VTE, some stud-
ies have shown that arterial thrombosis manifested 
by myocardial infarction (MI) or ischemic stroke 
may be caused by PC/PS deficiency with other pre-
disposing factors involvement [38–40]. Sayin et al. 
has found that left main coronary artery (LMCA) 
thrombus accompanied by embolization of the left 
anterior descending artery (LAD) in a 37-year-old 
man with normal coronary arteries was caused by 
PC and PS deficiency [38]. In this case cigarette 
smoking was considered to be a contributory fac-
tor leading to endothelial dysfunction. A large 
family cohort study demonstrated that heredi-
tary PC (PC antigen < 63% and/or activity < 64%) 
or PS (PS antigen < 68%) deficiency is associated 
with increased risk of arterial thrombosis, defined 
as MI, ischemic stroke or transient ischemic attack, 
before age 55 years, but not in older subjects [40].
Indications for PC/PS 
Deficiencies Diagnostic 
Testing
1. VTE without obvious cause < 45–50 years.
2. VTE in patients with a family history of 
thrombosis.
3. recurrent VTE.
4. Thrombosis at an unusual location.
5. Developing VTE during pregnancy, use 
of oral contraceptives or hormone replacement 
therapy.
In asymptomatic patients with PC/PS deficien-
cy thromboprophylaxis is not recommended.
Blood Sample Collection 
and Processing for PC/PS 
Deficiency Testing
For routine screening of PC deficiency the ami-
dolytic PC assay is recommended as more func-
tional and specific than coagulation assays [41]. 
PC antigen is generally assayed by ELISA [18]. Im-
munoassays for free and total PS are preferred for 
screening, and clotting assays for PS activity (Ta-
ble 1). If the results of functional and antigenic as-
says do not confirm the diagnosis unequivocally, 
genetic testing is indicated [14]. 
Testing should be done at least several weeks 
(3–6 months) after an acute clotting event to allow 
acute-phase reactant proteins to return to base-
line [29, 42].
PC/PS deficiency should not be diagnosed or 
excluded on the basis of assays performed when the 
patient is taking vitamin K antagonist (VKA) [18]. 
To avoid false-positive test results, plasma samples 
should be taken after temporary interruption of oral 
anticoagulant therapy for at least 10 days [42] and, 
in some cases, bridging anticoagulation with alterna-
tive agents such as LMWH [26]. Positive test results 
should be confirmed by a second blood sample.
In pregnant women, positive test results should 
be established after the postpartum period [42]. To 
prove inherited deficiency, testing of family mem-
bers is recommended.
Both patient and family members should re-
ceive genetic counseling prior to genetic testing, 
and such testing should only be performed after 
obtaining consent.
Additional factors influencing plasma PC/PS 
levels are summarized in Table 1.
Molecular Diagnosis
Genetic analysis by DNA sequencing is the im-
portant tool in the diagnosis of PC and PS defi-
ciencies. The presence of the PS pseudogene re-
quires careful primer design to avoid amplification 
of pseudogene fragments [14]. When no point mu-
tations within PROC or PROS1 genes have been 
found by routine methods, the multiplex ligation-
dependent probe amplification (MLPA) is a use-
ful technique for the detection copy number vari-
ation involving duplication or deletions from one 
or more exons to the whole gene [24, 25]. It should 
be noted, however, that genetic analysis of patients 
with PC levels above 70% and PS levels above 55% 
is not recommended because of the very low like-
lihood of detection a mutation associated with in-
herited PC or PS deficiencies [13].
Thromboprophylaxis with LMWH 
(Dalteparin, Enoxaparin and 
Nadroparin) or Unfractionated 
Heparin (UFH) According to Polish 
Guidelines for the Prevention 
and Treatment of Venous 
Thromboembolism, 2012
Both suggested thromboprophylaxis in asymp-
tomatic individuals with a PC/PS deficiency and 
thromboprophylaxis indicated after VTE event in-
cludes following groups of patients:
- in pregnancy and puerperium,
- in the perioperative period,
- at the time of internal medicine hospitaliza-
tion (thromboprophylaxis should not be used in 
patients at high-risk of bleeding, e.g., liver damage 
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INr > 1.5, thrombocytopenia < 50 × 103/ul, serious 
bleeding in last 3 months).
After VTE event prophylactic or intermediate 
doses of LMWH should be used in patients who 
have previously interrupted anticoagulation. Ther-
apeutic doses (after two incidents), adjusted or in-
termediate, should be used in patients who have 
previously applied anticoagulation.
Prophylactic PC concentrate should be admin-
istrated prior the invasive procedures with high 
risk of thrombosis, bleeding or prior the child-
birth, at the initial dose of 100 U/kg followed by 
30–50 U/kg every 12–24 h until PC > 100% (mini-
mal PC activity 20–50%).
Indications for extended anticoagulation after 
one episode of VTE:
– anticoagulant therapy for up to 2 years with-
out other thrombophilia,
– life-long if other thrombophilia is present 
(coexistence of PC/PS heterozygous deficiency 
with FV Leiden or prothrombin 20210A).
PS and PC Deficiencies with 
Known Genetic Background 
in Polish Patients
So far the authors identified two mutations re-
sponsible for PC deficiency and two mutations re-
sponsible for PS deficiency in Polish patients who 
have been referred to the Centre for Coagulation 
Disorders, John Paul II Hospital, Krakow, Poland.
A missense mutation in a PROC gene, a het-
erozygous nucleotide substitution G > C in codon 
109 resulting in the replacement of glycine for argi-
nine (G109r) associated with PC deficiency was de-
scribed for the first time in a 28-year-old male Pol-
ish patient, who was admitted due to acute MI with 
anterior wall ST-segment elevation (STEMI) 8 h af-
ter the pain onset. Coronary angiography revealed 
a thrombus in the LMCA leading to an 80% diame-
ter stenosis and distal embolization of LAD; whereas 
the remaining vessels were normal. The patient re-
ceived clopidogrel with a glycoprotein IIb/IIIa in-
hibitor (abciximab) and unfractionated heparin 
with the subsequent intravenous infusion. Twenty-
four hours after angiography enoxaparin at thera-
peutic doses was initiated with clopidogrel and as-
pirin. After 7 days, a repeat coronary angiography 
showed no evidence of residual thrombus in LMCA 
or LAD. The patient was discharged on dual anti-
platelet therapy with enoxaparin (maintained for 
6 months) and after a year clopidogrel was discon-
tinued. The patient remains on aspirin indefinite-
ly. PC antigen values were reduced to 46% and 59% 
on the two respective occasions (reference range, 
65–140%). In this case the patient’s risk factors in-
cluding heavy smoking, hypercholesterolemia, and 
obesity in combination with genetic thrombophilic 
factor caused the LMCA thrombus [43].
The second PROC mutation discovered in 
a Polish patient was a heterozygous nucleotide 
T > C substitution in codon 106 resulting in the 
replacement of cysteine by arginine (C106r) 
which has not been reported so far in the liter-
ature. A 29-year-old, obese male patient experi-
enced first-ever proximal DVT of the left leg fol-
lowing trauma and the subsequent high-risk PE 
with hypotonia that was successfully treated with 
tenecteplase, a fibrinolytic agent. The patient 
started therapy with acenocoumarol with a tar-
get INr value of 2 to 3. His family history of was 
negative. on two separate occasions PC activ-
ity was 42% (reference range, 70–140%), while 
PC antigen were 44% and 41% (reference range, 
65–140%), respectively. The diagnosis of the type 
I PC deficiency was established (Wypasek 2013, 
unpublished data).
The first Polish case of PS deficiency with ge-
netic characterization has been reported in a young 
male patient, who experienced idiopathic DVT at 
the age of 24 and was treated with enoxaparin for 
5 months. A few months later he developed ede-
ma of the right calf and right popliteal vein throm-
bosis was diagnosed. He started acenocoumarol at 
a daily dose of 2–3 mg with a target INr of 2 to 3. 
Family history revealed idiopathic DVT complicat-
ed with post-thrombotic syndrome in the patient’s 
mother at the age of 45 and two episodes of DVT in 
her sister. The free PS level was 18.9% in the patient 
(male reference range 74–146%) and 17.6% in the 
patient’s mother (female reference range 55–124%). 
Similar results were obtained on two separate occa-
sions. Total PS in both patients were reduced to 40 
and 44%, respectively (reference range 70–120%). 
Type I PS deficiency was diagnosed. MLPA analysis 
profile suggested a large deletion involving exons 1 
to 12 of the PROS1 gene, present at the heterozygous 
state in both the proband and his mother [44].
Another report associated with PS deficiency 
was the Heerlen polymorphism, a missense ser-
ine 501 to proline exchange (S501P) resulting in 
thymine to cytosine transition in exon 13 of the 
PROS1 gene. The association between the PS Heer-
len and venous thromboembolism (VTE) is not 
clearly established. The prevalence of the S501P 
mutation is high in the healthy European popu-
lation (0.5%) and data on the association between 
PS Heerlen and thrombosis are inconsistent [45]. 
It was shown that the PS Heerlen may be involved 
in the occurrence of VTE when other genetic risk 
factors like FV Leiden, prothrombin G20210A or 
antiphospholipid antibodies are present [46].
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PS Heerlen has been reported in a 50-year- 
-old man with several thrombotic episodes of 
deep and superficial veins and a highly positive 
thrombotic family history. He was successfully 
treated with enoxaparin for 3 months but refused 
anticoagulation with VKA taking only low-dose 
aspirin. The free PS levels were reduced to 52.8% 
and 55.8% on the two separate occasions (refer-
ence range 74–146%). Total PS was 110.5% (ref-
erence range 75–140%). Type III PS deficiency 
combined with FV Leiden and primary antiphos-
pholipid syndrome was diagnosed [47].
The current evidence indicates that screen-
ing for inherited thrombophilia, including defi-
ciencies in natural anticoagulants like PC and PS, 
should be conducted in young patients with VTE 
and in selected cases of stroke or MI in particular if 
a family history for thrombosis is positive. Patients 
with low PC and PS levels and the known muta-
tion within PROC or PROS1 genes combined with 
other genetic or environmental thrombosis factors 
are at increased risk of recurrent thromboembol-
ic events and require lifelong oral anticoagulation 
even after the first episode. Given positive family 
history including deaths from VTE among first de-
gree relatives, genetic counseling in such families 
should be implemented and appropriate thrombo-
prophylaxis in high-risk states should be consid-
ered in asymptomatic carriers.
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